Novo Nordisk A/S Common Stock (NY:NVO)

The pharmaceutical leader is gradually laying the groundwork for a strong rebound.

Topics Economy

3 Reasons to Buy Novo Nordisk Stock Right Now ↗

September 25, 2025

NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm Before September 30th

September 24, 2025

From Bragar Eagel & Squire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

September 24, 2025

From Pomerantz LLP

Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick ↗

September 22, 2025

Via Stocktwits

Topics Intellectual Property

Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset ↗

September 24, 2025

Via Benzinga

Topics ETFs

NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO

September 23, 2025

From The Rosen Law Firm PA

Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug.

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug ↗

September 23, 2025

Via Investor's Business Daily

Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape

September 22, 2025

As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating...

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Topics Artificial Intelligence Economy Intellectual Property

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

Topics Economy Intellectual Property

Roche Targets Top Spot In Weight Loss Drug Market ↗

September 22, 2025

Via Benzinga

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity...

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron

September 22, 2025

Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO

Topics Economy

September 22, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO

September 22, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

3 Dirt-Cheap Stocks to Buy Right Now ↗

September 22, 2025

These stocks share several common denominators, including attractive valuations.

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

Topics Intellectual Property

September 22, 2025

From Bernstein Liebhard LLP

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market ↗

September 22, 2025

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

Via Benzinga

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock ↗

September 20, 2025

Novo Nordisk (NVO) is a top GARP stock with strong growth, exceptional profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs ↗

September 20, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Is Novo Nordisk Stock a Buy Now? ↗

September 20, 2025

A lot has gone wrong for the drugmaker recently.

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

Topics Economy

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.

Topics Artificial Intelligence Economy Intellectual Property

Could This New Drug Be The Safer Way To Fight Obesity? ↗

September 19, 2025

Via Benzinga

Eli Lilly's Dual Triumph: Mounjaro Expands Reach, Orforglipron Set to Revolutionize Oral Diabetes and Weight Loss Market

September 19, 2025

Eli Lilly (NYSE: LLY) is poised to further solidify its dominance in the burgeoning diabetes and weight loss markets following a cascade of overwhelmingly positive clinical trial results for its...

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a...

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Topics Artificial Intelligence Economy Government

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

Topics Artificial Intelligence Economy Intellectual Property

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Oscar Health (OSCR) is drawing comparisons to Hims & Hers (HIMS) as short sellers may trigger a moonshot with ACA subsidies and a potential government shutdown.

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds ↗

September 19, 2025

Via Benzinga

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

September 19, 2025

From Faruqi & Faruqi LLP

NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm

September 19, 2025

From Bragar Eagel & Squire